Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,156.73
-17.8800-1.52%
Post-market: 1,161.574.84+0.42%19:59 EDT
Volume:3.06M
Turnover:3.54B
Market Cap:1.09T
PE:38.83
High:1,171.45
Open:1,168.47
Low:1,147.00
Close:1,174.61
52wk High:1,292.65
52wk Low:712.05
Shares:945.38M
Float Shares:939.00M
Volume Ratio:1.27
T/O Rate:0.33%
Dividend:6.69
Dividend Rate:0.58%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:32.28
PE(LYR):50.40

Loading ...

Leah Bennett: Where to Invest After the AI-Chip Stock Surge

Dow Jones
·
Jul 27

Dow Jones Top Company Headlines at 9 PM ET: Nvidia in Talks with Openai to Guarantee $250 Billion Financing for Data Center | Waymo ...

Dow Jones
·
Jul 27

Sector Update: Healthcare

MT Newswires Live
·
Jul 25

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atricure (ATRC)

TIPRANKS
·
Jul 24

Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements

TIPRANKS
·
Jul 24

As Lilly and Novo Clash in Court, Wall Street is Eyeing This Bigger Prize

Dow Jones
·
Jul 24

Dow Jones Top Company Headlines at 7 am ET: Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute over Weight-loss Ads | EU ...

Dow Jones
·
Jul 24

Novo Nordisk Seeks Preliminary Injunction Against Lilly Weight-loss Ads

Reuters
·
Jul 24

Novo Nordisk: Asked the Court to Preliminarily Halt Eli Lilly's Misleading Glp-1 Advertising Campaigns While Novo Nordisk’s Lawsuit Proceeds

THOMSON REUTERS
·
Jul 24

Lilly Stock is Rising on Plan to Seek Approval for Newest Weight-loss Drug in 2027

Dow Jones
·
Jul 24

Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug

TIPRANKS
·
Jul 23

Eli Lilly's Two Clinical Trials Meet Endpoints, Plans to File Next-Generation Weight Loss Drug by 2027

Deep News
·
Jul 23

Roche Prepares for Windfall from Eli Lilly's Obesity Pill

Dow Jones
·
Jul 23

Pre-Market: Nasdaq Futures Drop 0.83% as Google and Tesla Decline; European Borrowing Costs Surge

Deep News
·
Jul 23

Eli Lilly notes retatrutide met primary endpoint in TRIUMPH-2, TRIUMPH-3 trials

TIPRANKS
·
Jul 23

Lilly Targets Q1 2027 FDA Filing for Retatrutide Obesity Approval

Reuters
·
Jul 23

Eli Lilly Issues Press Release on Retatrutide Phase 3 Obesity Trial Results

Reuters
·
Jul 23

Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1c

THOMSON REUTERS
·
Jul 23

Eli Lilly: in Triumph-3, Adults with Severe Obesity & Established Cardiovascular Disease Lost up to Average of 55.8 Lbs (22.6%) at 80 Weeks

THOMSON REUTERS
·
Jul 23

Eli Lilly: Plans to Submit Biologics License Application for Retatrutide to FDA in Q1 2027

THOMSON REUTERS
·
Jul 23